Group highlights Our results demonstrate the achievement of key strategic goals that we set for the year.
We are confident that the investments we are making will be reflected in our future financial performance.
Our operating priorities for the year were Highlights to commence selling CroFab and DigiFab in the US, to initiate the Varisolve PEM Phase III programme and to expand our Total revenue range of marketed products and pipeline.
At the same time, 111.4m we achieved our key financial goals relating to revenue, gross margin, operating profit Recurring royalties Marketed product revenues and cash management during a year of 60.1m 35.4m substantial investment.
Milestones one-off income Biocompatibles revenues Total revenue increased by 13.1% to 9.9m 6.0m 111.4m.
Royalty revenues comprised recurring royalties of 60.1m, 11% higher than in the previous year, and milestones one-off income of 9.9m, 0.2m lower 6.0 than in the previous year.
Product revenues were 3% higher than in the previous year at 35.4 35.4m.
Our recurring revenues comprising recurring royalties and product revenues grew by 8% in total to 95.5m.
The contribution from Biocompatibles during the two months from 27 January to 31 March 2011 was 6.0m.
Our gross margin was 69.4%, an increase of 2.7%.
9.9 60.1 12 Business review BTG plc Annual Report and Accounts 2011 Business review Highlights Total revenue R&D expenditure Cash and cash equivalents 111.4m 32.1m 73.9m 09 10 98.5m 09 10 27.0m 09 10 82.6m 08 09 84.8m 08 09 21.6m 08 09 78.2m 07 08 75.0m 07 08 12.9m 07 08 57.0m 06 07 45.7m 06 07 9.7m 06 07 43.0m Includes held to maturity financial assets Operating profit before Loss before tax including 15.5m Profit after tax following acquisition adjustments of acquisition adjustments and a tax credit of 20.0m and reorganisation costs reorganisation costs 1.7m 10.8m 9.2m Gross margin Operating highlights Acute care sales coverage Initiation of three Varisolve 19 sales representatives and 69.4% PEM Phase III trials in two medical science liaisons the US recruited in to our acute 09 10 66.7% Acquisition of Biocompatibles care field force International plc Direct representation in 08 09 56.3% Establishment of US acute 22 states: sales coverage care sales force in all states 07 08 57.2% Accelerated transition of marketing rights for CroFab 06 07 58.6% and DigiFab Approval of ZYTIGA abiraterone acetate Initiation of Phase IIb study of AZD9773 CytoFab 13 BTG plc Annual Report and Accounts 2011 Business review
